Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report first quarter 2022 financial results on Wednesday, May 4, 2022, after U.S. financial markets close. Management will host a con...
Global Blood Therapeutics is enjoying strong fundamental improvement amid the biotech bear market. Sales of lead drug Oxbryta are ramping up aggressively. With the recent FDA approval to expand Oxbryta's label for children, you can expect more rapid sales growth this year. F...
Baker Brothers’ 13F portfolio value decreased from $22.77B to $20.55B this quarter. Incyte and Legend Biotech stakes were increased this quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~63% of the portfolio. For f...
Gadopiclenol Marketing Authorization dossier submissions accepted for review by EMA and FDA PR Newswire Priority Review granted by US-FDA March 28, 2022 VILLEPINTE, France , March 29, 2022 /PRNewswire/ -- Guerbet (FR0000032526 GBT), a gl...
SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the Guggenheim Genomic Medicines & Rare Disease Day on Friday, April 1, 2022, at 12:00 p.m....
The past year was a transformational time for Global Blood Therapeutics. The company was able to report growth for its flagship product, Oxbryta, in the face of COVID-19 headwinds. The company recently reported mixed earnings and revealed a hefty cash position. Global Blood Therap...
SOUTH SAN FRANCISCO, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- The GBT Foundation, a 501(c)(3) organization primarily funded by Global Blood Therapeutics, Inc. (GBT), today announced it is accepting proposals for the Access to Care Empowerment for Sickle Cell (ACE) Grant Program , ...
Image source: The Motley Fool. Global Blood Therapeutics (NASDAQ: GBT) Q4 2021 Earnings Call Feb 23, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Global Blood Therapeutics (GBT) Q4 2021 Earnings Call Transcript ...
Global Blood Therapeutics, Inc. (GBT) Q4 2021 Earnings Conference Call February 23, 2022 04:30 PM ET Company Participants Ted Love - President and CEO Jeff Farrow - Chief Financial Officer David Johnson - Chief Commercial Officer Kim Smith-Whitley - EVP and Head of R&D Steven Immergut - S...
Global Blood Therapeutics press release (NASDAQ:GBT): Q4 GAAP EPS of -$1.36 misses by $0.23. Revenue of $56.1M (+35.8% Y/Y) beats by $0.65M. Cash, cash equivalents, and marketable securities totaled $734.8 million at December 31, 2021, compared with $560.9 million at&...
News, Short Squeeze, Breakout and More Instantly...
Global Blood Therapeutics Inc. Company Name:
GBT Stock Symbol:
NASDAQ Market:
Guerbet to Spotlight the Novel New Drug Elucirem™ (gadopiclenol) injection at the 2022 Radiological Society of North America Scientific Assembly and Annual Meeting PR Newswire Join us at Booth #1711 Opportunity to learn about the recently US FDA-approved nov...
The healthcare industry is growing at an unprecedented rate, and healthcare stocks are poised to benefit from this growth. This is large because healthcare companies are developing innovative new treatments and technologies that are transforming the way we care for our health. As a resu...
NEW YORK, NY / ACCESSWIRE / September 22, 2022 / New York, New York-Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: EVO Payments...